ASH 2022 | Long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in R/R FL

Yeah, so this is the extended follow-up of our study of obinutuzumab, polatuzumab vedotin, the anti CD79B antibody-drug conjugate and lenalidomide in patients with relapsed/refractory follicular lymphoma. This study is a long-term follow-up for this study and 46 patients are available for long-term follow up. The eligibility population, we’ve already published the initial data from this study. Just to reiterate, this was a heavily pre-treated population with 88% of patients with grade three or four disease. More than half of patients had primary refractory disease and also were POD24-positive to their first line therapy. So this was a heavily pretreated patient population. The median number of prior lines of therapy was three. Our overall response rate that was independently assessed was 71% with a CR rate of between 74% with a CR rate of 61% by modified Lugano criteria. Then there were five additional crs who did not receive bone marrow. So that would’ve brought the CR rate up to 71%. So a CR rate probably in the high sixties to low seventies at the most conservative estimate in the mid-sixties.

What this abstract really demonstrates is that there are no new safety signals. All of the toxicity related to this therapy was very common toxicities that were associated with the three drugs and there were no unusual or additive toxicities for patients who had clinical benefit, who had a PR or better or stable disease PR or cr, who went on to receive maintenance therapy for up to two years. obinutuzumab 2 months for two years in lenalidomide for an additional year, there were no new or concerning safety signals. I think the most exciting thing is that with long-term follow up, with a median follow up now of 3.6 years, our median progression-free survival has not been reached. This is really exciting data because what this represents is that the majority of patients who’ve now been off therapy for two years or more have not relapsed, and that at 3.6 years of follow up, we have a median progression-free survival that has not been reached. I think this is really comparable to any of the therapies in follicular lymphoma that are approved today and is a well tolerated and highly active regimen.